Simeone discussed the design of BASECAMP-1, an observational study for patients previously treated for solid tumors who are at a high risk of relapse.
For patients with metastatic solid tumors, such as colorectal cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer, currently available treatment options are limited, especially when surgical resection is not curative.
Diane Simeone, MD, Laura and Isaac Perlmutter professor of surgery, Department of Surgery, NYU Grossman School of Medicine, recently presented a poster on the design and rationale of A2 Biotherapeutics’ BASECAMP-1 clinical trial (NCT04981119) at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, November 8-12, 2022, in Boston, Massachusetts. BASECAMP-1 is an observational study intended to evaluate patients who have been treated for solid tumors and are at a high risk of relapse. The study will seek to identify patients with somatic human leukocyte antigen loss of heterozygosity (HLA LOH), specifically those with LOH for HLA-A*02, who could potentially benefit from A2 Biotherapeutics’ logic-gated Tmod chimeric antigen receptor T-cell (CAR-T) therapy, which will be evaluated in the EVEREST clinical trial. These patients will undergo leukapheresis, with their cells stored for future manufacture of the CAR-T therapy in the event that they relapse.
In an interview with CGTLive, Simeone discussed the current unmet needs for patients with metastatic solid tumors, highlighting the need for immunotherapy approaches when patients experience relapse after surgery. She then described the design of the BASECAMP-1 and EVEREST studies.